Анализ акций 540694.BO
54
Нет оценки
Количественный анализ Eyestock не покрывает акции ANG Lifesciences India Ltd.
Рейтинг
Для оценки качества бизнеса компании мы собрали все финансовые данные из отчетов и представили их в виде одного числа - рейтинга компании. Значение рейтинга 100 является пороговым для определения актуальной инвестиционной идеи.
Низкий рейтинг
Капитализация млрд. $
0.002
Дивидендная доходность
0.16 %
Оборот
13.06 млрд
Сайт компании
https://anglifesciences.com/ANG Lifesciences India Ltd. engages in the manufacture and marketing of finished pharmaceutical formulations in a form of sterile dry powder for injection vials. The company is headquartered in Amritsar, Punjab and currently employs 545 full-time employees. The company went IPO on 2017-09-08. The firm is engaged in the business of manufacturing and marketing of finished pharmaceutical formulations in a dosage form of sterile dry powder injection vials. The company operates in two segments, namely pharmaceuticals and printing and packagings. The firm's products portfolio includes various products comprising therapeutic categories, such as Antibiotics, Antiviral, Antimalarial, Antiulcer, Carbapenem, Corticosteroid, Penicillin and Beta Lactamase Inhibitor. The company is engaged in the business of manufacturing and sales of finished pharmaceutical formulations in a dosage form of Dry Powder Injection Vials, Liquid Injections Vials, Ampoules, PFS, Hard Gelatin Capsules, Tablets, Soft Gelatin Capsules, Dry Syrups, Liquid Syru ps and Suspension, and Lotions, among others. The firm's subsidiaries include ANG Lifesciences India Limited and Mansa Prints and Publishers Limited.